ARS Pharmaceuticals, Inc. Selling, General and Administrative Expense
ARS Pharmaceuticals, Inc. (SPRY) reported Selling, General and Administrative Expense of $77.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $77.58M, a 42.84% increase year-over-year.
- ARS Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $72.20M, a 75.66% increase year-over-year.
- ARS Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $59.95M, a 68.93% increase year-over-year.
- ARS Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $74.75M, a 287.69% increase year-over-year.
- ARS Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2025 was $230.12M, a 221.06% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2024 was $71.67M, a 51.58% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2023 was $47.28M, a 7741.46% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2022 was $603.00K.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $77.58M 10-Q · filed 2026-08-13 | $149.78M 10-Q · filed 2026-08-13 | $209.74M derived: sum of 3 quarters · filed 2026-08-13 | $284.49M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $72.20M 10-Q · filed 2026-05-15 | $132.16M derived: sum of 2 quarters · filed 2026-05-15 | $206.91M derived: sum of 3 quarters · filed 2026-05-15 | $261.22M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $59.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $134.71M derived: sum of 2 quarters · filed 2026-03-09 | $189.02M derived: sum of 3 quarters · filed 2026-08-13 | $230.12M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $74.75M 10-Q · filed 2025-11-10 | $129.06M derived: sum of 2 quarters · filed 2026-08-13 | $170.17M 10-Q · filed 2025-11-10 | $205.66M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $54.31M 10-Q · filed 2026-08-13 | $95.42M 10-Q · filed 2026-08-13 | $130.91M derived: sum of 3 quarters · filed 2026-08-13 | $150.19M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $41.10M 10-Q · filed 2026-05-15 | $76.60M derived: sum of 2 quarters · filed 2026-05-15 | $95.88M derived: sum of 3 quarters · filed 2026-05-15 | $104.82M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $35.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $54.77M derived: sum of 2 quarters · filed 2026-03-09 | $63.72M derived: sum of 3 quarters · filed 2026-03-09 | $71.67M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $19.28M 10-Q · filed 2025-11-10 | $28.23M derived: sum of 2 quarters · filed 2025-11-10 | $36.18M 10-Q · filed 2025-11-10 | $43.01M derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-06-30 | $8.94M 10-Q · filed 2025-08-13 | $114.00K 10-Q · filed 2024-08-06 | $16.90M 10-Q · filed 2025-08-13 | $208.00K 10-Q · filed 2024-08-06 | $23.72M derived: sum of 3 quarters · filed 2025-08-13 | $38.70M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $7.96M 10-Q · filed 2025-05-14 | $93.00K 10-Q · filed 2024-05-09 | $14.78M derived: sum of 2 quarters · filed 2025-05-14 | $29.76M derived: sum of 3 quarters · filed 2025-05-14 | $29.94M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $6.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $21.80M derived: sum of 2 quarters · filed 2025-03-20 | $21.98M derived: sum of 3 quarters · filed 2025-03-20 | $47.28M 10-K · filed 2025-03-20 | $940.00K 10-K · filed 2024-03-21 | ||
| 2023-09-30 | $14.98M 10-Q · filed 2024-11-13 | $15.16M derived: sum of 2 quarters · filed 2024-11-13 | $40.46M 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | $181.00K 10-Q · filed 2024-08-06 | $518.00K 10-Q · filed 2024-08-06 | |||||
| 2023-03-31 | $337.00K 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | $603.00K 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |